{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"85.6","upperLimit":"90.1","value":"87.87"},{"groupId":"OG001","lowerLimit":"83.6","upperLimit":"91.1","value":"87.31"},{"groupId":"OG002","lowerLimit":"85.5","upperLimit":"91.5","value":"88.50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"915"},{"groupId":"OG001","value":"335"},{"groupId":"OG002","value":"488"}],"units":"Participants"}],"description":"OS of VHR-B-ALL post-Induction patients who receive a modified MBFM-IMHDM regimen that contains a second IM (Control Arm) compared to patients receive the cyclophosphamide + etoposide containing regimen (Experimental Arm 1). OS time is defined as time from enrollment to death or date of last contact for patients who are alive. 4-year OS will be estimated for the two randomized arms using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Total Non-DS VHR B-ALL patients","id":"OG000","title":"Non-DS VHR B-ALL Overall"},{"description":"Non-DS VHR patients receive a modified MBFM-IMHDM regimen that contains a second IM (Control Arm)","id":"OG001","title":"Non-DS VHR B-ALL Control Arm"},{"description":"Non-DS VHR patients receive cyclophosphamide + etoposide containing regimen (Experimental Arm 1)","id":"OG002","title":"Non-DS VHR B-ALL Experimental Arm 1"}],"paramType":"NUMBER","populationDescription":"VHR B-ALL patients with post induction therapies (includes patients from AALL0932). Experimental Arm 2 was closed early in the study due to excessive toxicities. The objectives and study design for VHR patients was modified to be limited to the two arms (Control vs Experimental Arm 1). Inevaluable and ineligible patients were also excluded from analysis.","reportingStatus":"POSTED","timeFrame":"At 4 years","title":"Overall Survival (OS) Rate for VHR B-ALL Patients, Overall and by Randomized Arm.","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}